Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Mol Cancer Res. 2013 Dec 27;12(3):359–369. doi: 10.1158/1541-7786.MCR-13-0526

Figure 7. The RNA-binding domain is required for RBM24 to inhibit p63 expression.

Figure 7

(A) Schematic representation of wild-type RBM24, ΔRNP1, and ΔRNP2. (B) Neither ΔRNP1 nor ΔRNP2 are able to bind to the p63 3′UTR. REMSA was performed by incubating 32P-labeled probe C with recombinant GST or GST-tagged RBM24, ΔRNP1, or ΔRNP2. The bracket indicates the RNA-protein complexes. (C) The RNA-binding domain is required for RBM24 to inhibit p63 expression. HaCaT cells were transiently transfected with a control vector or a vector expressing RBM24, ΔRNP1, or ΔRNP2 for 48 h. The relative level of ΔNp63α was normalized to that of actin and arbitrary set as 1.0 in control cells. The relative fold changes were shown below each lane.